Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$0.86
-7.5%		$2.49
$0.83
▼
$16.68
$960K0.888.22 million shs103,327 shs
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$0.48
$0.61
$0.00
▼
$8.75
$843K0.6853,314 shsN/A
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
$0.08
-7.0%		$0.33
$0.07
▼
$10.50
$543K1.8872,815 shs26,520 shs
SKYAW
SkyAI, Inc. Warrant
$0.03
+20.6%		$0.03
$0.01
▼
$0.20
$263KN/A30,643 shs3,798 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-7.46%-16.50%-28.33%-55.21%-86.04%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
0.00%-8.65%-23.20%-35.80%-93.19%
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
-6.96%-30.47%-55.18%-83.79%-99.12%
SKYAW
SkyAI, Inc. Warrant
+20.56%-9.12%-6.27%-5.38%+28.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$0.86
-7.5%		$2.49
$0.83
▼
$16.68
$960K0.888.22 million shs103,327 shs
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$0.48
$0.61
$0.00
▼
$8.75
$843K0.6853,314 shsN/A
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
$0.08
-7.0%		$0.33
$0.07
▼
$10.50
$543K1.8872,815 shs26,520 shs
SKYAW
SkyAI, Inc. Warrant
$0.03
+20.6%		$0.03
$0.01
▼
$0.20
$263KN/A30,643 shs3,798 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-7.46%-16.50%-28.33%-55.21%-86.04%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
0.00%-8.65%-23.20%-35.80%-93.19%
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
-6.96%-30.47%-55.18%-83.79%-99.12%
SKYAW
SkyAI, Inc. Warrant
+20.56%-9.12%-6.27%-5.38%+28.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
1.00
SellN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
1.50
ReduceN/AN/A
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
1.67
Reduce$7.009,086.35% Upside
SKYAW
SkyAI, Inc. Warrant
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SKYAW, BJDX, LYRA, and RBOT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/A$8.43 per shareN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$600K1.41N/AN/A$8.86 per share0.05
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
N/AN/AN/AN/A$7.89 per shareN/A
SKYAW
SkyAI, Inc. Warrant
$396.90K0.66N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$6.85M-$11.63N/AN/AN/AN/A-144.27%-115.00%8/19/2026 (Estimated)
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
-$93.43M-$19.15N/AN/AN/A-5,491.17%-1,010.91%-58.92%8/11/2026 (Estimated)
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
-$63.22M-$6.69N/AN/AN/AN/A-184.13%-112.50%8/6/2026 (Estimated)
SKYAW
SkyAI, Inc. Warrant
N/AN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)

Latest SKYAW, BJDX, LYRA, and RBOT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026N/A
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$3,520.00N/AN/AN/AN/AN/A
8/11/2026Q1 2026
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
-$1.54N/AN/AN/A$0.10 millionN/A
8/6/2026Q2 2026
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
-$1.15N/AN/AN/AN/AN/A
5/7/2026Q1 2026
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/A-$1.95N/A-$1.95N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/AN/AN/AN/AN/A
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
N/AN/AN/AN/AN/A
SKYAW
SkyAI, Inc. Warrant
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/A
2.81
2.81
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/A
2.43
2.43
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
N/A
4.75
4.75
SKYAW
SkyAI, Inc. Warrant
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
18.47%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
95.62%
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
47.27%
SKYAW
SkyAI, Inc. Warrant
N/A

Insider Ownership

CompanyInsider Ownership
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
6.10%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
3.25%
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
11.11%
SKYAW
SkyAI, Inc. Warrant
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
91.03 million972,000Not Optionable
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
501.78 million1.72 millionNo Data
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
2107.12 million5.89 millionNo Data
SKYAW
SkyAI, Inc. Warrant
38.81 millionN/ANot Optionable

Recent News About These Companies

Short Interest in Sharps Technology, Inc. (NASDAQ:STSSW) Expands By 50.9%
October 24, 2025  |  defenseworld.netD
Sharps Technology reminds shareholders to vote ‘FOR’ reverse stock split
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/sharps-technology-reminds-shareholders-to-vote-for-reverse-stock-split-1034498570
Sharps Technology, Inc. (STSS): Among the Most Active US Stocks to Buy According to Hedge Funds
March 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/sharps-technology-inc-stss-among-the-most-active-us-stocks-to-buy-according-to-hedge-funds/ar-AA1B4UNK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bluejay Diagnostics stock logo

Bluejay Diagnostics NASDAQ:BJDX

$0.86 -0.07 (-7.46%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.86 0.00 (-0.35%)
As of 07/31/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Lyra Therapeutics stock logo

Lyra Therapeutics NASDAQ:LYRA

$0.48 0.00 (0.00%)
As of 07/31/2026

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Vicarious Surgical stock logo

Vicarious Surgical NYSE:RBOT

$0.08 -0.01 (-6.96%)
As of 07/31/2026 03:58 PM Eastern

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

SkyAI, Inc. Warrant NASDAQ:SKYAW

$0.03 +0.01 (+20.56%)
As of 07/31/2026 12:16 PM Eastern

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas